# Anti-PD-1 and Chemotherapy for R/R Hodgkin Lymphoma

> **NCT03664323** · — · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 30 (actual)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Evaluate the improvement in response from the end of anti-PD-1 monotherapy

## Key facts

- **NCT ID:** NCT03664323
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-31
- **Primary completion:** 2018-01-31
- **Final completion:** 2018-06-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03664323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03664323, "Anti-PD-1 and Chemotherapy for R/R Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03664323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*